Standard: this guide onlyAll-Access Lifetime: all 45 guides + downloadsEducational content only
Hexarelin Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Hexarelin at a glance
What it is
A synthetic six-amino-acid growth hormone-releasing peptide (GHRP) and ghrelin-receptor agonist, structurally related to GHRP-6
Researched for
Growth hormone secretion and, in exploratory studies, cardiovascular (CD36-mediated) research contexts
Commonly reported range
100-200 mcg per injection is the range described in community sources (not a recommendation)
Route reported
Subcutaneous injection is the route most commonly described
Reported frequency
Community sources describe 2-3 times daily
Reported cycle
Short cycles (often described as ~4-8 weeks, or 2 weeks on/2 weeks off) due to reported desensitization
Plasma half-life
Reported at roughly 55-80 minutes
Regulatory status
Not FDA-approved; investigational only; WADA-prohibited (S2) in sport; sold for laboratory research use only
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
Hexarelin is a synthetic hexapeptide belonging to the growth hormone secretagogue (GHS) class, closely related in structure to GHRP-6 but modified for improved metabolic stability. It is reported to act primarily at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor targeted by the natural hormone ghrelin, stimulating the pituitary to release pulses of growth hormone. In published comparisons it is described as one of the more potent GHRPs, generating GH pulses reported to exceed those of GHRP-6 and GHRP-2 at equivalent molar doses. A distinctive feature reported in the literature is its interaction with the CD36 scavenger receptor in cardiac tissue, a pathway studied separately from its GH-releasing action. Because it works on the ghrelin/GHS-R1a axis rather than the GHRH pathway, it is often discussed alongside GHRH analogs, which act on a complementary signaling cascade.
Researched effects
Research and community sources report increased pulsatile growth hormone secretion and, secondarily, changes in downstream IGF-1 signaling following administration. Exploratory studies have also examined CD36-mediated effects in cardiac tissue as a research question distinct from GH release. It is important to note these are research findings and reported observations, not guaranteed outcomes; Hexarelin is investigational and has not been approved as safe or effective for any therapeutic use in humans.
Evidence & regulatory status
Evidence: Studied in the 1990s and early 2000s as a growth hormone secretagogue, with pharmacology literature reporting potent GH release via GHS-R1a and separate CD36-mediated cardiac interactions; human data remain limited and largely short-term.
Regulatory: Not FDA-approved for any indication; investigational only. Explicitly named on the WADA Prohibited List (S2, peptide hormones/growth factors) and prohibited in and out of competition for athletes.
Research use: Sold and labeled strictly for laboratory research use only, not for human consumption, clinical, or veterinary use; research-grade labeling does not exempt the molecule from WADA jurisdiction.
Dosage — reported ranges (overview)
The figures below are examples of what is reported in research and community sources, not a recommendation or a personal dose. Community discussions commonly describe 100-200 mcg per subcutaneous injection, given 2-3 times daily, with entry-level examples around 100 mcg once or twice daily. Because Hexarelin is reported to cause pituitary desensitization with continued use, sources frequently describe short cycles (for example ~4-8 weeks, or intermittent 2-weeks-on/2-weeks-off schedules) rather than continuous administration. None of this constitutes medical guidance.
The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.
Reconstitution — bac-water math
Hexarelin is supplied as a lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic water before any measurement. Because it is dosed in micrograms (mcg), the useful figure is concentration in mcg per mL: concentration (mcg/mL) = (vial mg x 1000) / mL of water added. On a U-100 insulin syringe, 100 units = 1 mL, so a dose in units = dose (mcg) / concentration (mcg/mL) x 100. Worked example: a 5 mg vial reconstituted with 2 mL of water gives 5000 mcg / 2 mL = 2500 mcg/mL. A 200 mcg example dose would then be 200 / 2500 x 100 = 8 units on a U-100 syringe. This is concentration math only, not a personal dose.
Bac water added
Concentration
100 mcg dose
200 mcg dose
1 mL
5000 mcg/mL (5 mg/mL)
2 units
4 units
2 mL
2500 mcg/mL (2.5 mg/mL)
4 units
8 units
3 mL
1667 mcg/mL (1.67 mg/mL)
6 units
12 units
This is concentration math, not a dose recommendation.
Pre-fills example values. Every field remains editable.
The amount printed on the vial or listed on a product page.
mL
Liquid volume used for the concentration calculation.
The mass amount to convert into liquid volume for this math example.
4. Insulin syringe size
Your result
Syringe-unit reading
10 units
= 0.1 mL · 250 mcg target amount
Concentration
2.5mg/mL
Per insulin unit
25mcg
Portions per vial
20
Volume
0.1mL
This calculator is an educational tool for laboratory and research math only. The peptides referenced are research compounds not intended for human or veterinary use, and example values are not medical advice or personal-use instructions. Follow applicable research protocols and regulations.
How the calculator works
Concentration
peptide ÷ liquid
Total peptide divided by liquid volume gives the concentration per mL.
Volume
target ÷ concentration
The target mass divided by concentration gives the liquid volume.
Syringe units
volume × 100
For insulin units, 100 units equals 1 mL, so mL is multiplied by 100.
Worked example: A 5 mg vial plus 2 mL liquid creates a 2.5 mg/mL concentration. A 250 mcg target amount equals 0.1 mL, or 10 insulin units. The vial contains 20 such portions.
Frequently asked questions
How much bacteriostatic water should I enter?+
There is no single calculator-default amount. The liquid volume controls concentration: more liquid creates a less concentrated solution and a larger volume reading for the same target amount; less liquid creates a more concentrated solution and a smaller volume reading.
How do insulin syringe units relate to mL?+
For this math tool, 100 insulin units equals 1 mL, and 1 unit equals 0.01 mL. The 0.3 mL, 0.5 mL, and 1.0 mL options change capacity, not the unit-to-mL relationship.
What is the difference between mg, mcg, and units?+
Milligrams and micrograms measure peptide mass: 1 mg = 1,000 mcg. Syringe units measure liquid volume. Reconstitution math connects mass and volume by using concentration.
Does changing the liquid volume change the total peptide in the vial?+
No. The total peptide amount entered for the vial remains fixed. Changing the liquid volume only changes concentration and the resulting volume shown by the calculator.
Injection / administration basics
In the research literature the route most commonly described is subcutaneous injection using a U-100 insulin syringe, into subcutaneous tissue such as the abdomen. Sources describe rotating injection sites and standard aseptic handling. Because GHRPs are reported to blunt GH release when co-administered with food, community sources often describe administration in a fasted state, away from meals. This describes what is reported in a research context and is not instruction for human use.
Half-life & frequency rationale
Hexarelin's plasma half-life is reported at roughly 55-80 minutes following subcutaneous administration, consistent with its short-acting, pulsatile GH-releasing profile. This short duration is the reason multiple daily administrations are described in the literature.
Side effects, safety & contraindications
Human safety data are limited and mostly derived from short-term studies. Among GHRPs, Hexarelin is reported to have one of the highest tendencies to raise cortisol, prolactin and ACTH, with these elevations described even at standard research doses. Other effects reported in the GHRP class include transient increases in hunger, water retention, tingling or numbness, head rush, and injection-site reactions. A well-documented limitation is rapid desensitization: rodent and human data report attenuation of the GH response with repeated or prolonged dosing, which is why short or intermittent cycles are commonly described. These are reported observations, not a complete safety profile.
Stacking — overview
In community and research discussion, Hexarelin (a GHRP acting on GHS-R1a) is most often paired with a GHRH analog, because the two act on complementary pathways and are reported to amplify the GH pulse more than either alone. Sources note this pairing is a general GHRP+GHRH strategy rather than a Hexarelin-specific clinical protocol, and that Hexarelin's stronger cortisol/prolactin profile makes some researchers prefer milder GHRPs for extended work. The following reflect commonly described pairings, not recommendations.
GH-axis stack
Hexarelin (GHRP) + CJC-1295 or Mod GRF 1-29 (the classic GHRP + GHRH pairing)
Alternative GHRH pairing
Hexarelin + Sermorelin
Storage & handling
Lyophilized: reported as stable refrigerated at 2-8°C, and can be kept frozen for longer-term storage; keep sealed and protected from light and moisture until reconstituted.
Reconstituted: store refrigerated at 2-8°C, use within roughly 2-4 weeks, keep away from light, and do not freeze the reconstituted solution.
References
Information is synthesized from peptide pharmacology literature on growth hormone secretagogues, the current WADA Prohibited List, and publicly available research and community sources; all figures are reported examples for educational use only and not medical advice.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
What is Hexarelin and what is it used for in research?
Hexarelin is a synthetic six-amino-acid growth hormone-releasing peptide (GHRP) and ghrelin-receptor agonist. In research it has been studied for its potent stimulation of growth hormone release and, separately, for CD36-mediated interactions in cardiac tissue. It is investigational only and not approved for any therapeutic use.
How does Hexarelin differ from other GHRPs like GHRP-6 or Ipamorelin?
Hexarelin is reported as one of the most potent GHRPs, producing larger GH pulses than GHRP-6 or GHRP-2 at equivalent molar doses. Its trade-off is that it is also reported to raise cortisol and prolactin more than milder options such as Ipamorelin, and to desensitize the pituitary more quickly.
Is Hexarelin legal or FDA-approved?
Hexarelin is not FDA-approved for any indication and is sold only for laboratory research use, not human consumption. It is explicitly named on the WADA Prohibited List (S2) and is banned for athletes in and out of competition.
Why do sources describe cycling Hexarelin?
Because Hexarelin is reported to cause pituitary desensitization, with the GH response diminishing over continued use, community and research sources commonly describe short or intermittent cycles (for example ~4-8 weeks or 2-weeks-on/2-weeks-off) rather than continuous administration.
How is Hexarelin reconstituted?
It is supplied as a lyophilized powder and reconstituted with bacteriostatic water. Concentration in mcg/mL equals (vial mg x 1000) divided by the mL of water added; a dose in units on a U-100 syringe equals dose in mcg divided by concentration, times 100. This is concentration math only, not a personal dose.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
